CTAGE family member 7, pseudogeneGenealiases: CTAGE7 · CTAGEP · bA500G10.2 · rcCTAGE5
Q-omics provides the consensus-scored CTAGE7P profile across patient tissues and cancer cell-line models. CTAGE7P expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CTAGE7P is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CTAGE7P RNA expression shows 19,375 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where CTAGE7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE7P survival associations across molecular data types. CTAGE7P RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE7P RNA expression–survival associations across cancer types. High CTAGE7P expression shows unfavorable associations in KIRC and KICH, but favorable associations in HNSC, SKCM, READ and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CTAGE7P RNA expression.
This table summarizes CTAGE7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE7P shows higher tumor expression in KIRC, BLCA, COAD, LIHC, HNSC and STAD. The KIRC box plot shows higher CTAGE7P RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p < 0.001).
This table shows molecular features associated with CTAGE7P in patient tissues and cancer cell lines. In patient samples, CTAGE7P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAGE7P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
